BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...an independent member of its board; Lonberg was formerly scientific director at GenPhar Inc. and Medarex Inc....
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

...with first-in-class molecules, including the 2001 deal for Erbitux cetuximab and the 2009 acquisition of Medarex Inc....
...Co-development and co-commercialization deal for first-in-class Erbitux cetuximab from ImClone Systems Inc. 7/22/09 - Acquired Medarex Inc....
...of the recession, BMS’s market cap hovered around $40 billion. Its July 2009 acquisition of Medarex Inc....
BioCentury | Sep 28, 2018
Tools & Techniques

Deconstructing tox in immuno-oncology

...toxicities in standard preclinical models, he said. Beatty noted that a preclinical safety report on Medarex Inc.’s...
...monkey studies, yet failed to detect any notable clinical or pathological toxicity. BMS partnered with Medarex...
BioCentury | Sep 7, 2018
Clinical News

AZ's anifrolumab misses in Phase III for lupus

...to co-develop anifrolumab, which was generated using Medarex’s UltiMAb technology. Bristol-Myers Squibb Co. (NYSE:BMY) acquired Medarex...
BioCentury | Aug 31, 2018
Clinical News

AZ's anifrolumab misses in Phase III for lupus

...to co-develop anifrolumab, which was generated using Medarex’s UltiMAb technology. Bristol-Myers Squibb Co. (NYSE:BMY) acquired Medarex...
BioCentury | May 18, 2018
Clinical News

Novartis to start head-to-head trial of Cosentyx and Tremfya

...and moderately to severely active Crohn's disease (CD). Stelara was generated using UltiMAb technology from Medarex Inc....
BioCentury | Jan 5, 2018
Clinical News

Novartis' canakinumab reduces CV risk in CANTOS subgroup

...Mediterranean fever (FMF). Ilaris is a human anti-IL-1 beta mAb that uses UltiMAb technology from Medarex Inc....
BioCentury | Nov 9, 2017
Clinical News

J&J's Stelara headed for Phase III in lupus

...moderately to severely active Crohn’s disease (CD). J&J’s Stelara was generated using UltiMAb technology from Medarex Inc....
BioCentury | Sep 1, 2017
Clinical News

Canakinumab reduces lung cancer mortality, headed for Phase III

...arthritis. Sales of the drug were $283 million in 2016. Ilaris uses UltiMAb technology from Medarex Inc....
BioCentury | Jun 23, 2017
Clinical News

Novartis' canakinumab reduces CV risk in MI patients

...and gouty arthritis. Ilaris is a human anti-IL-1 beta mAb that uses UltiMAb technology from Medarex Inc....
Items per page:
1 - 10 of 1064
BioCentury | Sep 18, 2020
Emerging Company Profile

Synthekine launches with $82M to create new cytokine signals

...an independent member of its board; Lonberg was formerly scientific director at GenPhar Inc. and Medarex Inc....
BioCentury | Jan 5, 2019
Product Development

Bristol-Myers’ next phoenix act?

...with first-in-class molecules, including the 2001 deal for Erbitux cetuximab and the 2009 acquisition of Medarex Inc....
...Co-development and co-commercialization deal for first-in-class Erbitux cetuximab from ImClone Systems Inc. 7/22/09 - Acquired Medarex Inc....
...of the recession, BMS’s market cap hovered around $40 billion. Its July 2009 acquisition of Medarex Inc....
BioCentury | Sep 28, 2018
Tools & Techniques

Deconstructing tox in immuno-oncology

...toxicities in standard preclinical models, he said. Beatty noted that a preclinical safety report on Medarex Inc.’s...
...monkey studies, yet failed to detect any notable clinical or pathological toxicity. BMS partnered with Medarex...
BioCentury | Sep 7, 2018
Clinical News

AZ's anifrolumab misses in Phase III for lupus

...to co-develop anifrolumab, which was generated using Medarex’s UltiMAb technology. Bristol-Myers Squibb Co. (NYSE:BMY) acquired Medarex...
BioCentury | Aug 31, 2018
Clinical News

AZ's anifrolumab misses in Phase III for lupus

...to co-develop anifrolumab, which was generated using Medarex’s UltiMAb technology. Bristol-Myers Squibb Co. (NYSE:BMY) acquired Medarex...
BioCentury | May 18, 2018
Clinical News

Novartis to start head-to-head trial of Cosentyx and Tremfya

...and moderately to severely active Crohn's disease (CD). Stelara was generated using UltiMAb technology from Medarex Inc....
BioCentury | Jan 5, 2018
Clinical News

Novartis' canakinumab reduces CV risk in CANTOS subgroup

...Mediterranean fever (FMF). Ilaris is a human anti-IL-1 beta mAb that uses UltiMAb technology from Medarex Inc....
BioCentury | Nov 9, 2017
Clinical News

J&J's Stelara headed for Phase III in lupus

...moderately to severely active Crohn’s disease (CD). J&J’s Stelara was generated using UltiMAb technology from Medarex Inc....
BioCentury | Sep 1, 2017
Clinical News

Canakinumab reduces lung cancer mortality, headed for Phase III

...arthritis. Sales of the drug were $283 million in 2016. Ilaris uses UltiMAb technology from Medarex Inc....
BioCentury | Jun 23, 2017
Clinical News

Novartis' canakinumab reduces CV risk in MI patients

...and gouty arthritis. Ilaris is a human anti-IL-1 beta mAb that uses UltiMAb technology from Medarex Inc....
Items per page:
1 - 10 of 1064